Myelodysplastic syndromes

American Journal of Clinical Pathology

Volumn 132, Issue 2, 2009, Pages 290-305

  Orazi, Attilio ^a   Czader, Magdalena B ^b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

MDS associated with an isolated del(5q) chromosomal abnormality; Myelodysplastic syndrome; Refractory anemia with excess blasts; Refractory anemia with ring sideroblasts; Refractory cytopenia with multilineage dysplasia; Refractory cytopenia with unilineage dysplasia

Indexed keywords

5Q- SYNDROME; APLASTIC ANEMIA; CANCER CLASSIFICATION; CANCER CYTODIAGNOSIS; CHROMOSOME 5Q; CHROMOSOME DELETION; CLINICAL FEATURE; CONFERENCE PAPER; CYTOGENETICS; DIAGNOSTIC APPROACH ROUTE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; HUMAN; IMMUNOPHENOTYPING; MOLECULAR GENETICS; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA;

HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 68549132622     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCPRCXX4R0YHKWV     Document Type: Conference Paper

References (79)

1. Brunning RD, Bennett J, Flandrin G, et al. Myelodysplastic syndromes. In: Jaffe ES, Harris NL, Stein H, et al, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:63-67.
2. Vardiman JW. Hematopathological concepts and controversies in the diagnosis and classification of myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2006:199-204.
3. Corey SJ, Minden MD, Barber DL, et al. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer. 2007;7:118-129.
4. Steensma DP. The spectrum of molecular aberrations in myelodysplastic syndromes: in the shadow of acute myeloid leukemia. Haematologica. 2007;92:723-727.
5. Frohling S, Scholl C, Gilliland DG, et al. Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol. 2005;23:6285-6295.
6. Look AT. Molecular pathogenesis of MDS. Hematology Am Soc Hematol Educ Program. 2005:156-160.
7. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature. 2008;451:335-340.
8. Steensma DP, List AF. Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity. Mayo Clin Proc. 2005;80:681-698.
9. Fenaux P. Chromosome and molecular abnormalities in myelodysplastic syndromes. Int J Hematol. 2001;73:429-437.
10. Shin MG, Kajigaya S, Levin BC, et al. Mitochondrial DNA mutations in patients with myelodysplastic syndromes. Blood. 2003;101:3118-3125.
11. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
12. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456-1465.
13. Gondek LP, Tiu R, O'Keefe CL, et al. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood. 2008;111:1534-1542.
14. Mohamedali A, Gaken J, Twine NA, et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood. 2007;110:3365-3373.
15. Atallah E, Garcia-Manero G. Treatment strategies in myelodysplastic syndromes. Cancer Invest. 2008;26:208-216.
16. Orazi A, O'Malley DP, Arber DA. Myelodysplastic syndromes. In: Illustrated Pathology of the Bone Marrow. New York, NY: Cambridge University Press; 2006:43-57.
17. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189-199.
18. Orazi A, Chiu R, O'Malley DP, et al. Chronic myelomonocytic leukemia: the role of bone marrow biopsy immunohistology. Mod Pathol. 2006;19:1536-1545.
19. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25:3503-3510.
20. Delacrétaz F, Schmidt PM, Piguet D, et al. Histopathology of myelodysplastic syndromes; the FAB classification (proposals) applied to bone marrow biopsy. Am J Clin Pathol. 1987;87:180-186.
21. Verburgh E, Achten R, Maes B, et al. Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes. J Clin Oncol. 2003;21:273-282.
22. Orazi A. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/ myeloproliferative diseases. Pathobiology. 2007;74:97-114.
23. Soligo DA, Oriani A, Annaloro C, et al. CD34 immunohistochemistry of bone marrow biopsies: prognostic significance in primary myelodysplastic syndromes. Am J Hematol. 1994;46:9-17.
24. Horny HP, Wehrmann M, Schlicker HU, et al. QBEND10 for the diagnosis of myelodysplastic syndromes in routinely processed bone marrow biopsy specimens. J Clin Pathol. 1995;48:291-294.
25. Baur AS, Meugé-Moraw C, Schmidt PM, et al. CD34/QBEND10 immunostaining in bone marrow biopsies: an additional parameter for the diagnosis and classification of myelodysplastic syndromes. Eur J Haematol. 2000;64:71-79.
26. Horny HP, Sotlar K, Valent P. Diagnostic value of histology and immunohistochemistry in myelodysplastic syndromes. Leuk Res. 2007;31:1609-1616.
27. Ramos F, Fernández-Ferrero S, Suárez D, et al. Myelodysplastic syndrome: a search for minimal diagnostic criteria. Leuk Res. 1999;23:283-290.
28. Brunning RD, Orazi A, Germing M, et al. Myelodysplastic syndromes. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008: 88-107.
29. Nearman ZP, Szpurka H, Serio B, et al. Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts. Am J Hematol. 2007;82:1076-1079.
30. Szpurka H, Tiu R, Murugesan G, et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood. 2006;108:2173-2181.
31. Rosati S, Mick R, Xu F, et al. Refractory cytopenia with multilineage dysplasia: further characterization of an "unclassifiable" myelodysplastic syndrome. Leukemia. 1996;10:20-26.
32. Balduini CL, Guarnone R, Pecci A, et al. Multilineage dysplasia without increased blasts identifies a poor prognosis subset of myelodysplastic syndromes. Leukemia. 1998;12:1655-1656.
33. Germing U, Gattermann N, Aivado M, et al. Two types of acquired idiopathic sideroblastic anaemia (AISA): a time-tested distinction. Br J Haematol. 2000;108:724-728.
34. Germing U, Gattermann N, Strupp C, et al. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res. 2000;24:983-992.
35. Howe RB, Porwit-MacDonald A, Wanat R, et al. The WHO classification of MDS does make a difference. Blood. 2004;103:3265-3270.
36. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23:7594-7603.
37. Matsuda A, Germing U, Jinnai I, et al. Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features of patients with refractory anemia according to the FAB classification. Leukemia. 2007;21:678-686.
38. Verburgh E, Achten R, Louw VJ, et al. A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification. Leukemia. 2007;21:668-677.
39. Giagounidis AA, Germing U, Wainscoat JS, et al. The 5q- syndrome. Hematology. 2004;9:271-277.
40. Pellagatti A, Hellström-Lindberg E, Giagounidis A, et al. Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes. Br J Haematol. 2008;142:57-64.
41. Florensa L, Vallespí T, Woessner S, et al. Incidence and characteristics of lymphoid malignancies in untreated myelodysplastic syndromes. Leuk Lymphoma. 1996;23:609-612.
42. Morrison VA, Rai KR, Peterson BL, et al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an Intergroup Study, Cancer and Leukemia Group B 9011. J Clin Oncol. 2002;20:3878-3884.
43. Barlogie B, Tricot G, Haessler J, et al. Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989. Blood. 2008;111:94-100.
44. Nilsson T, Nilsson L, Lenhoff S, et al. MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q). Genes Chromosomes Cancer. 2004;41:223-231.
45. Hake CR, Graubert TA, Fenske TS. Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients? Bone Marrow Transplant. 2007;39:59-70.
46. Giagounidis AA, Germing U, Aul C. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin Cancer Res. 2006;12:5-10.
47. Estey EH, Pierce S, Keating MJ. Identification of a group of AML/MDS patients with a relatively favorable prognosis who have chromosome 5 and/or 7 abnormalities. Haematologica. 2000;85:246-249.
48. Wimazal F, Fonatsch C, Thalhammer R, et al. Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface. Leuk Res. 2007;31:1461-1468.
49. Slovak ML, Gundacker H, Bloomfield CD, et al. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare "poor prognosis" myeloid malignancies. Leukemia. 2006;20:1295-1297.
50. Gupta R, Soupir CP, Johari V, et al. Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation. Br J Haematol. 2007;139:265-268.
51. Lambertenghi-Deliliers G, Orazi A, Luksch R, et al. Myelodysplastic syndromes with increased marrow fibrosis: a distinct clinico-pathologic entity. Br J Haematol. 1991;78:161-166.
52. Maschek H, Georgii A, Kaloutski V, et al. Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients. Eur J Haematol. 1992;48:208-214.
53. Pagliuca A, Layton DM, Manoharan A, et al. Myelofibrosis in primary myelodysplastic syndromes: a clinico-morphological study of 10 cases. Br J Haematol. 1989;71:499-504.
54. Steensma DP, Hanson CA, Letendre L, et al. Myelodysplasia with fibrosis: a distinct entity? Leuk Res. 2001;25:829-838.
55. Manoharan A, Horsley R, Pitney WR. The reticulin content of bone marrow in acute leukaemia in adults. Br J Haematol. 1979;43:185-190.
56. Orazi A, O'Malley DP, Jiang J, et al. Acute panmyelosis with myelofibrosis: an entity distinct from acute megakaryoblastic leukemia. Mod Pathol. 2005;18:603-614.
57. Thiele J, Kvasnicka HM, Orazi A. Bone marrow histopathology in myeloproliferative disorders: current diagnostic approach. Semin Hematol. 2005;42:184-195.
58. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092-1097.
59. Maschek H, Kaloutsi V, Rodriguez-Kaiser M, et al. Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics, and prognosis. Ann Hematol. 1993;66:117-122.
60. Orazi A, Albitar M, Heerema NA, et al. Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anemia by CD34 and PCNA immunostaining of bone marrow biopsy specimens. Am J Clin Pathol. 1997;107:268-274.
61. Kitagawa M, Kamiyama R, Kasuga T. Expression of the proliferating cell nuclear antigen in bone marrow cells from patients with myelodysplastic syndromes and aplastic anemia. Hum Pathol. 1993;24:359-363.
62. Matsui WH, Brodsky RA, Smith BD, et al. Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes. Leukemia. 2006;20:458-462.
63. Tuzuner N, Cox C, Rowe JM, et al. Hypocellular myelodysplastic syndromes (MDS): new proposals. Br J Haematol. 1995;91:612-617.
64. Orazi A, Cattoretti G, Soligo D, et al. Therapy-related myelodysplastic syndromes: FAB classification, bone marrow histology, and immunohistology in the prognostic assessment. Leukemia. 1993;7:838-847.
65. Guyotat D, Campos L, Thomas X, et al. Myelodysplastic syndromes: a study of surface markers and in vitro growth patterns. Am J Hematol. 1990;34:26-31.
66. Barrett J, Saunthararajah Y, Molldrem J. Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin Hematol. 2000;37:15-29.
67. Luzzatto L, Gianfaldoni G. Recent advances in biological and clinical aspects of paroxysmal nocturnal hemoglobinuria. Int J Hematol. 2006;84:104-112.
68. Kaiafa G, Papadopoulos A, Ntaios G, et al. Detection of CD55- and CD59-deficient granulocytic populations in patients with myelodysplastic syndromes. Ann Hematol. 2008;87:257-262.
69. Lim ZY, Killick S, Germing U, et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia. 2007;21:1436-1441.
70. Sloand EM, Rezvani K. The role of the immune system in myelodysplasia: implications for therapy. Semin Hematol. 2008;45:39-48.
71. Araten DJ, Swirsky D, Karadimitris A, et al. Cytogenetic and morphological abnormalities in paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2001;115:360-368.
72. Wang SA, Yue G, Hutchinson L, et al. Myelodysplastic syndrome with pure red cell aplasia shows characteristic clinicopathological features and clonal T-cell expansion. Br J Haematol. 2007;138:271-277.
73. Westhoff DD, Samaha RJ, Barnes A Jr. Arsenic intoxication as a cause of megaloblastic anemia. Blood. 1975;45:241-246.
74. Gregg XT, Reddy V, Prchal JT. Copper deficiency masquerading as myelodysplastic syndrome. Blood. 2002;100:1493-1495.
75. Wickramasinghe SN. Congenital dyserythropoietic anaemias: clinical features, haematological morphology and new biochemical data. Blood Rev. 1998;12:178-200.
76. O'Malley DP, Sen J, Juliar BE, et al. Evaluation of stroma in human immunodeficiency virus/acquired immunodeficiency syndrome-affected bone marrows and correlation with CD4 counts. Arch Pathol Lab Med. 2005;129:1137-1140.
77. Imashuku S, Kitazawa K, Ishii M, et al. Bone marrow changes mimicking myelodysplasia in patients with hemophagocytic lymphohistiocytosis. Int J Hematol. 2000;72:353-357.
78. Macheta M, Will AM, Houghton JB, et al. Prominent dyserythropoiesis in four cases of haemophagocytic lymphohistiocytosis. J Clin Pathol. 2001;54:961-963.
79. Florena AM, Iannitto E, Quintini G, et al. Bone marrow biopsy in hemophagocytic syndrome. Virchows Arch. 2002;441:335-344.